Does This News From the FDA Make Eli Lilly a Buy for 2025?

Motley Fool12-23 16:15

Eli Lilly sells one of the most sought-after types of drugs today: weight loss drugs. The company’s Zepbound and Mounjaro have brought in blockbuster revenue, and more growth could be on the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493739892?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801727%2Fgettyimages-1178121483.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-12-23 16:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493739892","market":"us","top_or_hot":-1,"title":"Does This News From the FDA Make Eli Lilly a Buy for 2025?","media":"Motley Fool","content":"<div>\n<p>Eli Lilly sells one of the most sought-after types of drugs today: weight loss drugs.\n\n\n\n\n\n\n\nThe company’s Zepbound and Mounjaro have brought in blockbuster revenue, and more growth could be on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/12/23/does-this-news-from-fda-make-eli-lilly-2025-buy/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does This News From the FDA Make Eli Lilly a Buy for 2025?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes This News From the FDA Make Eli Lilly a Buy for 2025?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-23 16:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/12/23/does-this-news-from-fda-make-eli-lilly-2025-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly sells one of the most sought-after types of drugs today: weight loss drugs.\n\n\n\n\n\n\n\nThe company’s Zepbound and Mounjaro have brought in blockbuster revenue, and more growth could be on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/12/23/does-this-news-from-fda-make-eli-lilly-2025-buy/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"https://www.fool.com/investing/2024/12/23/does-this-news-from-fda-make-eli-lilly-2025-buy/","article_id":"2493739892","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801727%2Fgettyimages-1178121483.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493739892","pubTimestamp":1734941700,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Eli Lilly sells one of the most sought-after types of drugs today: weight loss drugs.The company’s Zepbound and Mounjaro have brought in blockbuster revenue, and more growth could be on the horizon.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4007":"制药","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2063271972.USD":"富兰克林创新领域基金","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4516":"特朗普概念","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4599":"减肥药","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC"},"translate_title":"FDA的这一消息是否会让礼来公司成为2025年的买入对象？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"Eli Lilly sells one of the most sought-after types of drugs today: weight loss drugs.\n\n\n\n\n\n\n\nThe company’s Zepbound and Mounjaro have brought in blockbuster revenue, and more growth could be on the horizon. \n\nEli Lilly (LLY 1.35%) soared more than 60% from the start of the year through its peak this summer, thanks to the company's dominance in one of today's most in-demand areas: the obesity drug market. Lilly sells tirzepatide, a compound sold for weight loss under the name Zepbound and for type 2 diabetes under the name Mounjaro. But doctors have prescribed either one to patients trying to shed pounds, and both have become blockbusters.These drugs have helped the big pharma player report double-digit quarterly revenue growth. Demand has been so strong, that it earlier surpassed supply and pushed Lilly to increase its manufacturing capacity to keep up.The supply problem has been one of the biggest risks for Lilly. With the tirzepatide shortage, compounding pharmacies had the authorization to produce their own versions of the drug and sell them. This clearly limited Lilly's revenue opportunity.In recent days, though, news from the U.S. Food and Drug Administration (FDA) lifted this risk. The regulatory agency declared that there was no longer a shortage of tirzepatide -- and that means compounders must stop selling their alternate versions.Does this news make Lilly a buy for 2025?Image source: Getty Images.How Lilly's weight loss drugs workFirst, let's consider the full Lilly weight loss drug story. The company's drugs belong to a class known as dual GIP/GLP-1 receptor agonists, products that act on hormonal pathways involved in digestion. These drugs work by controlling blood sugar levels and appetite -- and their results have been fantastic both in clinical trials and in the real world.In a recent head-to-head study involving Novo Nordisk's Wegovy, Zepbound came out on top, resulting in average weight loss of about 20%, compared to more than 13% for the rival medicine. Lilly and Novo Nordisk both are leaders in this market today.Meanwhile, further studies of Zepbound are finding that it could address other health issues in those with obesity -- from heart failure to sleep apnea. Lilly has applied for regulatory review of the drug in those indications when accompanied by obesity and recently won approval for use in sleep apnea.A regulatory nod in these areas could be key for Lilly, and here's why: Today, Medicare only will cover weight loss drugs if they're approved for a second condition. So such an approval could expand the number of Zepbound patients.The major problem Lilly has faced in recent times, though, is difficulty meeting demand -- and that offered compounders the opportunity to take market share. Compounding pharmacies, as mentioned, are authorized to sell their versions of a pharma company's drug, often for a lower price, if that particular drug is on the FDA shortage list. Once the drug drops off the list, though, compounders must stop selling.Supply meeting demandRecently, the FDA removed tirzepatide from the shortage list, saying: \"[S]upply meets or exceeds current demand,\" and based on available information, \"[S]upply will also meet or exceed projected demand.\" This means that compounders now have 60 to 90 days, depending on the type of operation, to stop selling their versions of the drug. The FDA originally declared the shortage over back in October, then reviewed the situation a second time after a lawsuit from a compounding group.This clearly is positive news for Lilly because it means that patients now must turn to the pharma company for Zepbound or Mounjaro -- and the company can fully benefit from demand for the products. Even during the drug shortage, these products brought in billions of dollars in revenue, so it's likely that moving forward, with increased capacity and compounders' exit from the market, Lilly should see significant growth.Does this news make Lilly a buy for 2025? It's also important to look at the whole picture.Lilly sells a wide variety of other drugs across treatment areas, and in the recent quarter, three other major products -- Verzenio for breast cancer, immunology drug Taltz, and diabetes drug Humalog -- each delivered double-digit revenue growth. Today, Lilly stock trades for 57x forward earnings estimates, down from more than 70x just a couple of months ago. At the same time, the future looks brighter than ever, making Lilly a top pharma stock to buy for 2025 and hold onto for the long term.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493739892"}